On September 5, 2025 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) reported that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2025 World Conference on Lung Cancer ("WCLC") taking place on September 6-9, 2025 in Barcelona, Spain, and the Chinese Society of Clinical Oncology ("CSCO") Annual Meeting 2025, taking place on September 10-14, 2025 in Jinan, China (Press release, Hutchison China MediTech, SEP 5, 2025, View Source [SID1234655767]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Updated analysis from savolitinib’s SACHI, SAVANNAH and a Phase IIIb confirmatory study in non-small cell lung cancer ("NSCLC") patients will be presented at WCLC 2025. Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor ("TKI") being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Details of the WCLC 2025 presentations are as follows:

Abstract title Presenter / Lead author Presentation details

SPONSORED STUDIES
SAVANNAH: Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and / or Amp NSCLC
Christina Baik, University of Washington and Fred Hutchinson Cancer Center, Seattle, USA MA03.03
Mini Oral: New Advances in Circulating Biomarkers
Room 06
Sunday, September 7, 2025
3:15 – 4:30PM CEST
Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy
Yongfeng Yu, Shanghai Chest Hospital, Shanghai, China P3.12.48
Poster: Metastatic NSCLC – Targeted Therapy
Tuesday, September 9, 2025
Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation EGFR-TKI Failure: SACHI Study Insights
Lijuan Chen, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China P3.12.64
Poster: Metastatic NSCLC – Targeted Therapy
Tuesday, September 9, 2025
Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp And/Or Amp Post-Progression on Osimertinib: SAVANNAH PROs
Silvia Novello, University of Turin, San Luigi Hospital, Turin, Italy PT2.12.04
ePoster: Metastatic NSCLC – Targeted Therapy
Monday, September 8, 2025

INVESTIGATOR-INITIATED STUDIES
Efficacy and Safety of Surufatinib, Durvalumab in Combined with Chemotherapy as First-line Treatment of Extensive-stage Small-cell Lung Cancer Hui Zhang/ Ying Hu, Beijing Chest Hospital, Beijing, China P3.13.22
Poster: Small Cell Lung Cancer and Neuroendocrine Tumors
Tuesday, September 9, 2025

Clinical data of HMPL-653, a novel, selective and potent CSF-1R inhibitor, from a first-in-human Phase I study in patients with tenosynovial giant cell tumor in China will be presented for the first time at the CSCO Annual Meeting 2025. Details of the CSCO Annual Meeting 2025 presentations are as follows:

Abstract title Presenter / Lead author Presentation details

SPONSORED STUDIES
A first-in-human phase I study of HMPL-653, a CSF-1R inhibitor, in patients with tenosynovial giant cell tumor Xiaohui Niu 25297
Oral Session
Friday, September 12, 2025
15:00 – 15:12PM HKT

INVESTIGATOR-INITIATED STUDIES
Fruquintinib Plus Serplulimab as First-Line Therapy in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (nccRCC): Updated Efficacy and Safety from a Multicenter, Single-Arm Trial Jiwei Huang/ Wei Xue 23258
Oral Session
Thursday, September 11, 2025
16:50 – 17:15PM HKT
Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): updated data from a single-arm, phase II clinical trial Tianzhu Qiu/ Yanhong Gu 23766
Oral Session
Friday, September 12, 2025
11:20 – 12:00 noon HKT
Fruquintinib plus chemotherapy as second-line therapy in metastatic colorectal cancer: a multicenter, open-label, phase II clinical trial Yongshun Chen 22084
Poster Session
Efficacy and Safety of Neoadjuvant Fruquintinib plus Toripalimab and Short-Course Radiotherapy (SCRT) for Locally Advanced Rectal Cancer: Updated Results from a Phase II Clinical Trial Zhiping Li 21915
Abstract
Fruquintinib combined with chemotherapy as first-line treatment for advanced metastatic colorectal cancer: a propensity score‑matched comparison of efficacy between a prospective single-arm cohort and a retrospective observational cohort Fuxiang Zhou 23550
Abstract
Efficacy and safety of fruquintinib combined with PD-1 inhibitor and chidamide in MSS mCRC: a comparison with real-world bevacizumab plus anti-pd-1 and chidamide arm Miaomiao Gou 23591
Abstract
Phase ll Clinical Study of Surufatinib Combined with Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer Miaomiao Gou 23610
Oral Session
Friday, September 12, 2025
16:53 – 16:59PM HKT
A single-arm, Phase Ib/II trial of surufatinib plus KN046 and gemcitabine and nab-paclitaxel as first-line treatment for unresectable advanced pancreatic cancer Wenquan Wang/ Liang Liu 23783
Oral Session
Thursday, September 11, 2025
16:20 – 16:35PM HKT
Updated results of surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: a prospective, randomized, controlled trial Dan Cao 22652
Poster Session
Surufatinib in patients with soft tissue myeloma who have failed first-line standard chemotherapy or anlotinib: a multicenter, prospective, two-cohort, phase II clinical study Yuhong Zhou/ Xi Guo P80
Poster Session
Efficacy and Mechanistic Study of the NASCA Regimen (Surufatinib Combined with Camrelizumab, Nab-Paclitaxel, and S‑1) in Advanced Pancreatic Cancer Patients with Liver Metastasis Guanghai Dai/ Ru Jia 22309
Abstract
A Phase II, Single-Arm Study of Surufatinib Combined with Zimberelimab and Nab-Paclitaxel in Patients with Advanced Triple‑Negative Breast Cancer: Data Update Caixia Wang 23679
Abstract
Efficacy and safety of surufatinib combined with gemcitabine, cisplatin and immune checkpoint inhibitor for the treatment of unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma Xuetao Shi/ Jingtao Zhong 24133
Abstract
Efficacy and Safety of Surufatinib in Patients with Neuroendocrine Neoplasms: A Multicenter Retrospective Study Jiang Long 24294
Abstract